Finance

Lists
ELVN:NASDAQ
Enliven Therapeutics Inc
US$ ४०.९८
+०.८६%
(+०.३५) 1D
US$ ४०.९८
०.००% (०.००)
After hours
Closed: अक्टोबर ९, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELVN...
Open
US$ ४१.००
High
US$ ४२.०६
Low
US$ ४०.२९
Mkt. cap
३.०० अरब
Avg. vol.
१३.७० लाख
Volume
१०.०३ लाख
52-wk high
US$ ६२.३२
52-wk low
US$ १४.७८
EPS
-US$ १.६७
Beta
०.२४
Shares outstanding
७.३३ करोड
No. of employees
६७
Open
US$ ४१.००
High
US$ ४२.०६
Low
US$ ४०.२९
Mkt. cap
३.०० अरब
Avg. vol.
१३.७० लाख
Volume
१०.०३ लाख
52-wk high
US$ ६२.३२
52-wk low
US$ १४.७८
EPS
-US$ १.६७
Beta
०.२४
Shares outstanding
७.३३ करोड
No. of employees
६७
News stories
From web sources and news partners
About Enliven Therapeutics Inc
CEO-
Employees६७
Founded२०१६
Headquartersबोल्डर, कोलोराडो, संयुक्त राज्य अमेरिका
Sector-
Websiteimaratx.com
Analyst ratings
Based on 13 analysts giving stock ratings to ELVN in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for ELVN in the last 3 months.
Highest
Current US$ ४०.९८
US$ ८२.०० (+१००.१०%)
Average
US$ ७४.४५ (+८१.६७%)
Lowest
US$ ६८.०० (+६५.९३%)
Analyst
Recommendation
Action
Price target
Projected
Date
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
10/07/2026
Etzer Darout
Barclays
Buy
Maintained
US$ ७८.००
+९०.३%
10/07/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
10/06/2026
Sean Laaman
Morgan Stanley
Buy
Initiated
US$ ७०.००
+७०.८%
10/05/2026
Priyanka Grover
J.P. Morgan
Buy
Initiated
US$ ७५.००
+८३%
10/01/2026
Salim Syed
Mizuho Securities
Buy
Maintained
US$ ७३.००
+७८.१%
08/17/2026
Dara Azar
Stifel Nicolaus
Buy
Reiterated
US$ ८२.००
+१००.१%
08/13/2026
Sam Slutsky
LifeSci Capital
Buy
Reiterated
US$ ७०.००
+७०.८%
08/08/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
US$ ७५.००
+८३%
08/06/2026
Boris Peaker
JonesTrading
Buy
Reiterated
US$ ७०.००
+७०.८%
08/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
US$ ७८.००
+९०.३%
08/05/2026
Salveen Richter
Goldman Sachs
Buy
Reiterated
US$ ८०.००
+९५.२%
08/05/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
US$ ६८.००
+६५.९%
08/06/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ ६५.००
+५८.६%
07/09/2026
Unknown Analyst
Jefferies
Buy
Maintained
US$ ५९.००
+४४%
06/15/2026
Soumit Roy
JonesTrading
Buy
Maintained
US$ ४५.००
+९.८%
04/06/2026
Last report
२०२६ अगस्ट ५
Fiscal period
Q2 2026
-US$ ०.४९ / -US$ ०.३८
-२९.८०%miss
Revenue / Est. (USD)
- / ०.००
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
१.८२ करोड
२.१२ करोड
२.०७ करोड
२.९० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६८.७१ लाख
१.३० करोड
७१.३६ लाख
८२.१३ लाख
Operating expense
२.५१ करोड
३.४३ करोड
२.७८ करोड
३.७२ करोड
Total operating expenses
२.५१ करोड
३.४३ करोड
२.७८ करोड
३.७२ करोड
Operating income
-२.५१ करोड
-३.४३ करोड
-२.७८ करोड
-३.७२ करोड
Other non operating income
-
-
-
-८.०० हजार
EBT including unusual items
-२.०१ करोड
-२.९७ करोड
-२.३६ करोड
-३.२५ करोड
EBT excluding unusual items
-२.०१ करोड
-२.९७ करोड
-२.३६ करोड
-३.२५ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-२.०१ करोड
-२.९७ करोड
-२.३६ करोड
-३.२५ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.३२
-०.४८
-०.३८
-०.४९
Interest and investment income
४९.४८ लाख
४६.१८ लाख
४१.९६ लाख
४७.३२ लाख
Interest expense
-
-
-
-
Net interest expenses
४९.४८ लाख
४६.१८ लाख
४१.९६ लाख
४७.३२ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.५० करोड
-३.४२ करोड
-२.७८ करोड
-३.७२ करोड
Gain or loss from assets sale
-
१.०६ लाख
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू